CureVac SE
Tübingen, Germany
Purpose
to develop a CSP-based malaria vaccine candidate, driven by antigen-encoding mRNA technology, with the ability to induce high and long-lasting levels of anti-CSP antibodies and to protect against malaria challenge
Division
Global Health
Date
November 2017
Region Served
GLOBAL
Committed amount
$1,085,599
Grant topic
Malaria
Duration (months)
61
Grantee location
Tübingen, Germany
Related work
More about our financials
Our story
Learn about the origins of the foundation and the values that drive our work.
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.